AMGN

#58
Amgen Inc
387.96
+2.71%
Secteur:
Base:
Devise de Profit:
Range quotidien
387.96
388.16
Range Annuel
261.43
387.49
Changement quotidien
+2.71%
Changement Mensuel
+11.09%
Evolution sur 6 mois
+35.07%
Changement Annuel
+25.94%
Clôture Précédente
377.72
Open
388.16
Bid
Ask
Low
387.96
High
388.16
Volume
381
Open full chart

Financials

Overview Relevé Statistics Dividends
Quarterly Annual
  • Market Capitalization 208.72 B
  • Employee 32 K
  • Founded 1980
  • CEO Robert A. Bradway
  • Website www.amgen.com
  • Headquarter Delaware, United States
  • FIGI BBG000BBS2Y0
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
23
Price to sales ratio
4.83
Dividends per share
9.66
Dividend yield %
2.95

Amgen Inc

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000.

Nouvelles